Abstract
Viruses can manipulate the immune response against them by various strategies to influence immune cells, i.e. by over-activation leading to functional inactivation, bypassing antigen presentation or even suppression of effector functions. Little is known, however, about how these features of immune regulation and modulation could be used for therapeutic purposes. Reasons for this include the complexity of immune regulatory mechanisms under certain disease conditions and the risks that infections with viruses pose to human beings. The orf virus (ORFV), a member of the Parapoxvirus genus of the poxvirus family, is known as a common pathogen in sheep and goats worldwide. The inactivated ORFV, however, has been used as a preventative as well as therapeutic immunomodulator in veterinary medicine in different species. Here, we review the key results obtained in pre-clinical studies or clinical studies in veterinary medicine to characterise the therapeutic potential of inactivated ORFV. Inactivated ORFV has strong effects on cytokine secretion in mice and human immune cells, leading to an auto-regulated loop of initial up-regulation of inflammatory and Th1-related cytokines, followed by Th2-related cytokines that attenuate immunopathology. The therapeutic potential of inactivated ORFV has been recognised in several difficult-to-treat disease areas, such as chronic viral diseases, liver fibrosis or various forms of cancer. Further research will be required in order to evaluate the full beneficial potential of inactivated ORFV for therapeutic immunomodulation.
Similar content being viewed by others
References
Moss B (2007) Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, vol 2. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, pp 2905–2946
Haig DM, Mercer AA (1998) Ovine diseases. Orf. Vet Res 29:311–326
Weber O, Knolle P, Volk H-D (2007) Immunomodulation by inactivated Orf virus (ORFV)—therapeutic potential. In: Mercer AA, Schmidt A, Weber O (eds) Poxviruses. Birkhäuser, Basel, pp 297–310
Fleming SB, Mercer AA (2007) Genus Parapoxvirus. In: Mercer AA, Schmidt A, Weber O (eds) Poxviruses. Birkhäuser, Basel, pp 127–165
Mayr A, Büttner M, Wolf G, Meyer H, Czerny C (1989) Experimental detection of the paraspecific effects of purified and inactivated poxviruses. Zentralbl Veterinarmed B 36:81–99
Büttner M, Czerny CP, Lehner KH, Wertz K (1995) Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46:237–250
Mayr B, Mayr A (1995) Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature. Tierarztl Prax 23:542–552
Mayr A, Siebert M (1990) Untersuchungen über die Wirksamkeit des Paramunitätsinducers PIND-ORF auf den durch Transportstress ausgelösten Kortisolanstieg beim Pferd. Tierärztl Umsch 45:677–682
Ziebell KL, Steinmann H, Kretzdorn D, Schlapp T, Failing K, Schmeer N (1997) The use of Baypamun N in crowding associated infectious respiratory disease: efficacy of Baypamun N (freeze dried product) in 4–10 month old horses. Zentralbl Veterinarmed B 44(9):529–536
Mayr B, Deininger S, Büttner M (1991) Treatment of chronic stomatitis of cats by local paramunization with PIND-ORF. Zentralbl Veterinarmed B 38:78–80
Berg G, Rüsse M (1994) Der Einsatz von Baypamun HK in der Mammatumorbehandlung der Hündin. Tierärztl Umschau 49:476–480
Fachinger V, Schlapp T, Strube W, Schmeer N, Saalmüller A (2000) Poxvirus-induced immunostimulating effects on porcine leukocytes. J Virol 74:7943–7951
Schütze N, Raue R, Büttner M, Alber G (2009) Inactivated Parapoxvirus ovis activates canine blood phagocytes and T lymphocytes. Vet Microbiol 137:260–267
Mayr A, Rättig H, Stickl H, Alexander M (1979) Paramunität, Paramunisierung, Paramunitätsinducer. Teil 1. Geschichtliche Entwicklung, Begriffsbestimmung und Wesen. Fortschr Med 97:1159–1160, 1162–1165
Mayr A, Rättig H, Stickl H, Alexander M (1979) Paramunität, Paramunisierung, Paramunitätsinducer. Teil 2.: Paramunitätsinducer, eigene Untersuchungen, Diskussion. Fortschr Med 97:1205–1210
Marsig E, Stickl H (1988) The effectiveness of immunomodulators from microorganisms and of animal pox preparations against tumor cell lines in vitro. Zentralbl Veterinarmed B 35:601–609
Mayr A, Büttner M, Wolf G, Meyer H, Czerny C (1989) Experimental detection of the paraspecific effects of purified and inactivated poxviruses. Zentralbl Veterinarmed B 36:81–99
Lear A, Hutchison G, Reid HW, Norval M, Haig DM (1996) Phenotypic characterisation of the dendritic cells accumulating in ovine dermis following primary and secondary orf virus infections. Eur J Dermatol 6:135–140
Jenkinson DM, McEwen PE, Onwuka SK, Moss VA, Elder HY, Hutchison G, Reid HW (1990) The pathological changes and polymorphonuclear and mast cell responses in the skin of specific pathogen-free lambs following primary and secondary challenge with orf virus. Vet Dermatol 1:139–150
Haig D, McInnes C, Deane D, Lear A, Myatt N, Reid H, Rothel J, Seow H-F, Wood P, Lyttle D, Mercer A (1996) Cytokines and their inhibitors in orf virus infection. Vet Immunol Immunopathol 54:261–267
Haig DM, Hutchison G, Thomson J, Yirrell D, Reid HW (1996) Cytolytic activity and associated serine protease expression by skin and afferent lymph CD8+ T cells during orf virus reinfection. J Gen Virol 77(Pt 5):953–961
Haig DM, McInnes CJ (2002) Immunity and counter-immunity during infection with the Parapoxvirus orf virus. Virus Res 88:3–16
Haig D, Deane D, Percival A, Myatt N, Thomson J, Inglis L, Rothel J, Seow H-F, Wood P, Miller HRP, Reid HW (1996) The cytokine response of afferent lymph following orf virus reinfection of sheep. Vet Dermatol 7:11–20
Friebe A, Friederichs S, Scholz K, Janssen U, Scholz C, Schlapp T, Mercer A, Siegling A, Volk HD, Weber O (2011) Characterization of immunostimulatory components of orf virus (Parapoxvirus ovis). J Gen Virol 92(Pt 7):1571–1584
Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA (1997) A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 71:4857–4861
Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y (1998) Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J 17:5948–5963
Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJ (1994) Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68:84–92
Haig DM, McInnes CJ, Thomson J, Wood A, Bunyan K, Mercer A (1998) The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. Immunology 93:335–340
Deane D, McInnes CJ, Percival A, Wood A, Thomson J, Lear A, Gilray J, Fleming S, Mercer A, Haig D (2000) Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2. J Virol 74:1313–1320
McKeever DJ, Jenkinson DM, Hutchison G, Reid HW (1988) Studies of the pathogenesis of orf virus infection in sheep. Comp Pathol 99:317–328
Haig DM, McInnes CJ, Deane D, Reid HW, Mercer AA (1997) The immune and inflammatory response to orf virus. Comp Immunol Microbiol Infect Dis 20:197–204
Jenkinson DM, Hutchison G, Onwuka SK, Reid HW (1991) Changes in the MHC class II+ dendritic cell population of ovine skin in response to orf virus infection. Vet Dermatol 2:1–9
McKeever DJ, Reid HW, Inglis NF, Herring AJ (1987) A qualitative and quantitative assessment of the humoral antibody response of the sheep to orf virus infection. Vet Microbiol 15:229–241
Yirrell DL, Reid HW, Norval M, Howie SE (1989) Immune response of lambs to experimental infection with orf virus. Vet Immunol Immunopathol 22:321–332
Chand P, Kitching RP, Black DN (1994) Western blot analysis of virus-specific antibody responses for capripox and contagious pustular dermatitis viral infections in sheep. Epidemiol Infect 113:77–85
Kruse N, Weber O (2001) Selective induction of apoptosis in antigen-presenting cells in mice by Parapoxvirus ovis. J Virol 75:4699–4704
Chang WL, Baumgarth N, Yu D, Barry PA (2004) Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol 78:8720–8731
Castrucci G, Ferrari M, Osburn BI, Frigeri F, Barreca F, Tagliati S, Cuteri V (1996) A non-specific defence inducer in preventing clinical signs of infectious bovine rhinotracheitis in calves. Comp Immunol Microbiol Infect Dis 19:163–169
Castrucci G, Osburn BI, Frigeri F, Ferrari M, Salvatori D, Lo Dico M, Barreca F (2000) The use of immunomodulators in the control of infectious bovine rhinotracheitis. Comp Immunol Microbiol Infect Dis 23:163–173
Hammerl J, Wolf G, Berner H (1995) Klinische Untersuchungen zur Wirkung des Paramunitätsinducers Baypamun als Prophylaxe beim MMA-Komplex der Sau. Tierärztl Umsch 50:383–386
Kyriakis SC, Tzika ED, Lyras DN, Tsinas AC, Saoulidis K, Sarris K (1998) Effect of an inactivated Parapoxvirus based immunomodulator (Baypamun) on post weaning diarrhoea syndrome and wasting pig syndrome of piglets. Res Vet Sci 64:187–190
Diehl K, Rosychuk RA (1993) Feline gingivitis–stomatitis–pharyngitis. Vet Clin North Am Small Anim Pract 23(1):139–153
Zetner K, Stoian C, Benetka V, Möstl K, Groiss S, Saalmüller A (2006) Clinical results of a new treatment of feline gingivostomatitis with an immunomodulator (Zylexis®). Praktischer Tierarzt 87:678–687
Mayr A, Mayr B (1999) A new concept in prophylaxis and therapy: paramunization by poxvirus inducers. Pesq Vet Bras 19:91–98
Weber O, Siegling A, Friebe A, Limmer A, Schlapp T, Knolle P, Mercer A, Schaller H, Volk HD (2003) Inactivated Parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 84:1843–1852
Siegemund S, Hartl A, von Buttlar H, Dautel F, Raue R, Freudenberg MA, Fejer G, Büttner M, Köhler G, Kirschning CJ, Sparwasser T, Alber G (2009) Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated Parapoxvirus ovis. J Virol 83:9411–9422
Friebe A, Siegling A, Friederichs S, Volk H-D, Weber O (2004) Immunomodulatory effects of inactivated Parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 78:9400–9411
Friebe A, Friederichs S, Scholz K, Janssen U, Scholz C, Schlapp T, Mercer A, Siegling A, Volk H-D, Weber O (2011) Characterization of immunostimulatory components of Orf virus (Parapoxvirus ovis). J Gen Virol 92:1571–1584
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760
Dranoff G, Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417–454
Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109
Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D (2006) Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Curr Drug Metab 7:599–612
Fiebig H-H, Siegling A, Volk H-D, Friebe A, Knolle P, Limmer A, Weber O (2011) Inactivated orf virus (Parapoxvirus ovis) induces antitumoral activity in transplantable tumor models. Anticancer Res 31:4185–4190
Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC (2012) ORFV: a novel oncolytic and immune stimulating Parapoxvirus therapeutic. Mol Ther 20:1148–1157
Nowatzky J, Knorr A, Hirth-Dietrich C, Siegling A, Volk H-D, Limmer A, Knolle P, Weber O (2012) Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatol Res. 2012 Sep 13. doi:10.1111/j.1872-034X.2012.01086.x. [Epub ahead of print]
Baroni GS, D’Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A (1996) Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23:1189–1199
Weng H, Mertens PR, Gressner AM, Dooley S (2007) IFN-γ abrogates profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 46:295–303
Gurujeyalakshmi G, Giri SN (1995) Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 21:791–808
Shi MN, Zheng WD, Zhang LJ, Chen ZX, Wang XZ (2005) Effect of IL-10 on the expression of HSC growth factors in hepatic fibrosis rat. World J Gastroenterol 31:4788–4793
Shi MN, Huang YH, Zheng WD, Zhang LJ, Chen ZX, Wang XZ (2006) Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10. World J Gastroenterol 12(15):2357–2362
Friedman SL, Bansal MB (2006) Reversal of hepatic fibrosis—fact or fantasy? Hepatology 43(2 Suppl 1):S82–S88
El Bialy SA, El Kader KF, El-Ashmawy MB (2011) Current progress in antifibrotics. Curr Med Chem 18:3082–3092
Kisseleva T, Brenner DA (2011) Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 25:305–317
Seet BT, McCaughan CA, Handel TM, Mercer AA, Brunetti C, McFadden G, Fleming SB (2003) Analysis of an orf virus chemokine-binding protein: shifting ligand specificities among a family of poxvirus viroceptors. Proc Natl Acad Sci U S A 100:15137–15142
Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273–31282
Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J 18:363–374
Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA (1999) Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci U S A 96:3071–3076
McInnes CJ, Wood AR, Mercer AA (1998) Orf virus encodes a homolog of the vaccinia virus interferon-resistance gene E3L. Virus Genes 17:107–115
Westphal D, Ledgerwood EC, Hibma MH, Fleming SB, Whelan EM, Mercer AA (2007) A novel Bcl-2-like inhibitor of apoptosis is encoded by the Parapoxvirus ORF virus. J Virol 81:7178–7188
Mercer AA, Fleming SB, Ueda N (2005) F-box-like domains are present in most poxvirus ankyrin repeat proteins. Virus Genes 31:127–133
Camus-Bouclainville C, Fiette L, Bouchiha S, Pignolet B, Counor D, Filipe C, Gelfi J, Messud-Petit F (2004) A virulence factor of myxoma virus colocalizes with NF-kappaB in the nucleus and interferes with inflammation. J Virol 78:2510–2516
Johnston JB, Wang G, Barrett JW, Nazarian SH, Colwill K, Moran M, McFadden G (2005) Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J Virol 79:10750–10763
Diel DG, Delhon G, Luo S, Flores EF, Rock DL (2010) A novel inhibitor of the NF-κB signaling pathway encoded by the Parapoxvirus orf virus. J Virol 84:3962–3973
Diel DG, Luo S, Delhon G, Peng Y, Flores EF, Rock DL (2011) A nuclear inhibitor of NF-kB encoded by a poxvirus. J Virol 85:264–275
Diel DG, Luo S, Delhon G, Peng Y, Flores EF, Rock DL (2011) Orf virus ORFV121 encodes a novel inhibitor of NF-kB that contributes to virus virulence. J Virol 85:2037–2049
Steinmassl M, Wolf G (1990) Bildung von Interleukin 2 und Interferon-α durch mononukleäre Leukozyten des Schweines nach in vitro-Stimulation mit verschiedenen Viruspräüaraten. Zentralbl Veterinarmed B 37:321–331
Förster RJ, Wolf G (1990) Phagocytosis of opsonized fluorescent microspheres by equine polymorphonuclear leukocytes. Zentralbl Veterinarmed B 37:481–490
Förster R, Wolf G, Mayr A (1994) Highly attenuated poxviruses induce functional priming of neutrophils in vitro. Arch Virol 136:219–226
Mayr A, Büttner M, Pawlas S, Erfle V, Mayr B, Brunner R, Osterkorn K (1986) Vergleichende Untersuchungen über die immunstimulierende (paramunisierende) Wirksamkeit von BCG, Levamisol, Corynebakterium parvum, und Präparaten aus Pockenviren in verschiedenen in vivo- und vitro-Testen. Zentralbl Veterinarmed B 33:321–339
Vilsmeier B (1995) Entwicklung eines Zellkultur-Challenge-Tests zum Nachweis paramunisierender Aktivitäten verschiedener Präparationen aus Pockenviren. Thesis, München
Mayr A (1987) Untersuchungen über die paraspezifische Wirkung von Pockenviren. Drug Res 37:988
Conflict of interest
O.W. is an employee of Bayer. O.W., A.A.M. and H.-D.V. are co-inventors of patent applications on the use of ORFV virus. A.F. and P.K. declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weber, O., Mercer, A.A., Friebe, A. et al. Therapeutic immunomodulation using a virus—the potential of inactivated orf virus. Eur J Clin Microbiol Infect Dis 32, 451–460 (2013). https://doi.org/10.1007/s10096-012-1780-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-012-1780-x